Type 2 Diabetes

An analysis of data from more than 5500 people with type 1 diabetes and preserved kidney function at baseline suggests patients of African Caribbean ethnicity had a more than 50% greater risk of kidney function decline of 50% or greater than patients of other ethnic backgrounds.

Amy Hess-Fischl, MS, RD, LDN, BC-ADM, CDCES reviews the currently available rescue modalities for use in pediatric patients with diabetes experiencing severe hypoglycemia or very low blood sugar.

A certified diabetes educator comments on the some of the available resources for patients, their families, and school staff surrounding the management of diabetes in a school setting.

An analysis assessing the benefits of hybrid closed loop systems in patients with T1D has returned results suggesting improved glycemic control could help preserve neurological function among adolescents with type 1 diabetes.

An expert in diabetes education reviews the signs and symptoms of hypoglycemia and reviews the importance of having school staff members knowledgeable in their presentation.

Amy Hess-Fischl, MS, RD, LDN, BC-ADM, CDCES provide insight into the challenges inherent to the management of pediatric patients with diabetes, highlighting school related considerations.

An analysis of the FIDELITY program from ESC Congress 2022 details an 11% reduction in risk of all-cause mortality and a 25% reduction in risk of sudden cardiac death among patients with type 2 diabetes and chronic kidney disease.

Our endocrinology month in review spotlights the most popular content from the past month. Our top content from August 2022 includes a trial examining time-restricted eating, a pair of FDA decisions, coverage of ADCES 22, and more!

Using electronic medical record data from 2018-2020 obtained from 24 medical centers across the US, including Johns Hopkins, University of Colorado, and Mayo Clinic institutions, a new study suggests rates of youth onset type 2 diabetes increased 77% during the first year of the pandemic.

An analysis of patients treated in the Massachusetts General Brigham hospital system provides into the potential cardioprotective benefits of SGLT2 inhibitor use among patients with diabetes and cancer receiving treatment with anthracyclines.

In this episode of Diabetes Dialogue, which was filmed just days after the conclusion of ADCES 22, our hosts take the time to dive deeper into the conference, their favorite sessions, and how the ADCES meetings have evolved to the changing role of diabetes care and education specialists over the years.

Real time CGM was significantly greater time in range, lower time below range, and lower glycemic variability compared to intermittently scanned CGM.

An observational study of more than 300,000 with type 2 diabetes from Denmark suggests short-term use of NSAIDs was linked to a more than 40% increase in the likelihood of a first-time heart failure hospitalization.

In this article, readers will find a collection of the on-site coverage of the Association of Diabetes Care and Education Specialist (ADCES) 2022 annual meeting from Diabetes Dialogue: Therapeutics, Technology, & Real-World Perspectives.

Despite increasing the rate of diagnoses and healthcare utilization, the GEMS study found a lower glycemic criterion for diagnosis of gestational diabetes was not associated with a reduced risk of negative outcomes for mother and offspring.

Results from a new study highlighted the importance of achieving normal, stable glucose levels for individuals with type 2 diabetes.

In this edition of Diabetes Dialogue: Therapeutics, Technology, & Real-World Perspectives, which was filmed on-site at ADCES 22, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, sit down with Jennifer Clements, PharmD, following her sessions to discuss her work, her upcoming research interests, and ongoing trends in the field of diabetes management.

The participants who initiated insulin after implementation achieved significantly higher doses at 36 weeks.

Glargine and detemir insulin were modestly associated with a reduced risk of MACE compared to neutral protamine Hagedorn insulin.

Participants in the least deprived group had one quarter the odds of no change/increase in mean HbA1c compared with the most deprived group.

A conversation on advancements in diabetes, the rising cost of insulin, and advice regarding disease management.

26 weeks of treatment with empagliflozin reduced the myocardial glucose metabolic rate by 45.1% in patients with type 2 diabetes.

Gary Scheiner, MS, CDE, discusses updates in diabetes technologies from the ADCES annual meeting, the role of CDES in optimizing uptake and use of new technology, and the ADCES's push to advance diabetes management.

In this episode, the hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, sit down with ADCES 2022 Diabetes Care and Education Specialist of the Year Anastasia Albanese-O’Neill, PhD, to discuss her inspiration, her work within the field, and insight into the project she has decided to focus on during her year as ADCES Diabetes Care and Education Specialist of the Year.

Gary Scheiner, MS, CDE, discusses themes and topics of discussion at ADCES 22.